Pfizer To Close Two Former Hospira Sites In India
Executive Summary
Pfizer is set to close two of its manufacturing facilities in India this year, after the firm concluded that production at the former Hospira sites “is not viable” due to falling demand.
You may also be interested in...
Pfizer India Site Slammed By FDA
Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.
FDA Warning Letter Slams Pfizer Site In India On Sterility Testing, Environmental Monitoring
Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.
Manufacturing Roundup - 19 March 2019
Several firms are looking to expand their manufacturing capabilities through acquisitions and investments; however a number of companies are suffering setbacks. Biocon gets hit with six ‘Form 483’ observations across two sites in India, as Jubilant, Pfizer’s Hospira and Andapharm are slapped with FDA warning letters.